Clinical evaluation of oxaliplatin combined with S-1 or docetaxel for advanced gastric cancer
10.3760/cma.j.issn.1673-422X.2015.06.007
- VernacularTitle:奥沙利铂联合替吉奥或多西他赛治疗进展期胃癌的临床疗效分析
- Author:
Shirong YANG
;
Chengmao ZHAO
;
Rong WANG
;
Yuanzhong MU
;
Gang ZHAO
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms;
Drug therapy;
Oxaliplatin;
Docetaxel;
S-1
- From:
Journal of International Oncology
2015;(6):426-429
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of combination therapy of oxaliplatin and S-1 vs oxaliplatin and docetaxel for advanced gastric cancer (AGC)patients.Methods From April 201 1 to Janu-ary 201 3,62 cases of AGC were collected in the Fifth People′s Hospital of Qinghai Province.All cases were randomly divided into group A (31 cases)and B (31 cases)by random number table.In group A,oxaliplatin plus S-1 was administered,and in group B,oxaliplatin plus docetaxel was applied.The response rate (RR), time of diseases controlled rate (DCR),progression-free survival (PFS),overall survival (OS)and adverse reactions of the two groups were observed and compared.Results There were no statistically differences between group A and group B in RR (48.4% vs 54.8%),DCR (67.7% vs 77.4%),mPFS (5.4 months vs 6.2 months),mOS (9.0 months vs 9.8 months),and the statistical values were as follows:χ2 =0.26,P =0.71 1 ;χ2 =0.73,P =0.393;χ2 =0.51 ,P =0.473;χ2 =0.03,P =0.829.The incidence of degrees Ⅰ-Ⅱperipheral neuropathy (9.7% vs 22.6%),nausea and vomiting (1 2.9% vs 32.3%)in group A were signifi-cantly lower than those in group B (χ2 =5.78,P =0.002;χ2 =4.63,P =0.01 6).Conclusion Both the two chemotherapies are similar in therapeutic effect for patients with AGC.Oxaliplatin plus S-1 treatment may be better than oxaliplatin plus docetaxel in the tolerance of patients.
